ESET Mobile Antivirus Optimizes Heuristic Detection for Mobile Platform; Beta Delivers Unprecedented Speed and Accuracy SAN DIEGO — ESET, the…
Fortinet® — the pioneer and leading provider
of unified threat management (UTM) solutions — today announced that
Wisconsin’s Jefferson County has deployed Fortinet’s FortiGate®
multi-threat security appliances to help secure the county’s network
infrastructure by helping to provide antivirus, Web filtering, intrusion
prevention, firewall and secure virtual private network (VPN) connectivity.
As a result, the county has realized reduced network costs annually.
Working closely with JSO Technology LLC, a value-added reseller and
consulting firm focused on providing best-of-breed data security, network
infrastructure and network operating systems/application solutions and
services, Jefferson County sought out Fortinet as the new network security
vendor, allowing the County to simplify management of the network
infrastructure while reducing IT expenses.
Previously using Check Point and Websense for firewall and Web filtering,
Jefferson County was exceeding their budget in support costs. In addition,
it became tiresome for them to manage multiple log-in screens, each
requiring a different password and multiple vendor purchase orders. In
order to simplify and consolidate the network infrastructure and at the
same time save substantial amounts of money, Jefferson County turned to
Fortinet.
“We went from spending roughly $31,000 a year in support costs for two
network security functionalities to $4,000 a year for five functionalities
that are proving to work better. For an organization with a tight IT
budget, I don’t know how it gets better than that,” said Roland Welsch, IT
manager for Jefferson County.
Two FortiGate-800 appliances, deployed in high availability active/passive
mode, are located in Jefferson at the County’s data center. The FortiGate
appliances enable the 750 county employees to securely access data such as
county tax information, forms, the intranet and email. Originally
purchasing the appliances for firewall and Web filtering, the County added
antivirus, intrusion prevention and secure VPN connectivity.
Also deployed in Jefferson County is Fortinet’s FortiAnalyzer™-800.
FortiAnalyzer systems are purpose-built appliances that provide valuable
intelligence and simplify and centralize the collection and analysis of log
and event data from Fortinet’s FortiGate appliances, delivering highly
relevant network reports, valuable intelligence on network usage and
assistance with meeting regulatory compliance. With FortiAnalyzer,
Jefferson County’s IT staff can now easily create and send out weekly
reports on network usage.
“The consolidation of multiple security functions is allowing customers of
all sizes to easily and cost-effectively manage their network,” said Karl
Soderlund, vice president of Americas sales and business development for
Fortinet. “By consolidating multiple security functions into a single
platform, Fortinet gives customers the opportunity to add additional
security features on an as needed basis and in a cost-effective manner.”
Fortinet’s FortiGate systems are ASIC-accelerated security appliances that
integrate essential security applications and services such as antivirus,
firewall, VPN, intrusion prevention, Web filtering, anti-spam and traffic
shaping. All FortiGate systems are kept up to date automatically by
Fortinet’s FortiGuard® Network, which provides continuous updates to help
ensure protection against the most damaging, content-based threats from
email and Web traffic such as viruses, worms, intrusions and other unwanted
network traffic — around the clock and around the world.
About Fortinet ( www.fortinet.com )
Fortinet is the pioneer and leading provider of ASIC-accelerated unified
threat management, or UTM, security systems, which are used by enterprises
and service providers to increase their security while reducing total
operating costs. Fortinet solutions were built from the ground up to
integrate multiple levels of security protection — including firewall,
antivirus, intrusion prevention, VPN, spyware prevention and anti-spam –
designed to help customers protect against network and content level
threats. Leveraging a custom ASIC and unified interface, Fortinet solutions
offer advanced security functionality that scales from remote office to
chassis-based solutions with integrated management and reporting. Fortinet
solutions have won multiple awards around the world and are the only
security products that are certified in seven programs by ICSA Labs
(Firewall, Antivirus, IPSec, SSL, Network IPS, Anti-Spyware, and
Anti-spam). Fortinet is privately held and based in Sunnyvale, California.
Copyright© 2008 Fortinet, Inc. All rights reserved. Fortinet®, FortiGate®,
and FortiGuard®, are registered trademarks of Fortinet, Inc., and other
Fortinet names herein may also be trademarks of Fortinet. All other product
or company names may be trademarks of their respective owners. Performance
metrics contained herein were attained in internal lab tests under ideal
conditions. Network variables, different network environments and other
conditions may affect performance results, and Fortinet disclaims all
warranties, whether express or implied, except to the extent Fortinet
enters a binding contract with a purchaser that expressly warrants that the
identified product will perform according to the performance metrics
herein. For absolute clarity, any such warranty will be limited to
performance in the same ideal conditions as in Fortinet’s internal lab
tests. Fortinet disclaims in full any guarantees. Fortinet reserves the
right to change, modify, transfer, or otherwise revise this publication
without notice, and the most current version of the publication shall be
applicable. Certain Fortinet products are licensed under U.S. Patent No.
5,623,600.
Information provided by: Findarticles.com
LAS VEGAS — Titan IC Systems has developed a unique capability offering a flexible, yet high-performance solution for content processing for next-generation high-speed networks. Today Titan IC Systems announced a technology partnership with Altera Corporation, a world leader in FPGAs. As a result of many months of co-operation between the two companies, Titan’s novel Regular Expression Processor (RXP) has been optimized to benefit from the high-performance capability of Altera([R]) Stratix([R]) series FPGAs.
"This is a very important milestone for Titan IC Systems," said Godfrey Gaston, CEO of Titan IC Systems. "After a number of years of intense product development, we are delighted to be able to offer a unique solution to the real, complex problem of performing true regular expression processing at 20Gb/s on an FPGA fabric. Feedback from prospects has been overwhelming - we are clearly providing a capability that meets their performance requirements. The support from Altera has played a key role in the development process."
The RXP provides the ability to perform complex regular expression processing up to 20Gb/s on an FPGA fabric. It is unique since it offers complete flexibility to the customer, both for low-cost requirements as well as high-performance, computationally intensive tasks. This flexibility allows for both on-chip and off-chip memory, depending on the number of rules to be implemented. The novel parallel, concurrent architecture allows true 20Gb/s throughput for POSIX/PCRE compatible regular expressions. It facilitates applications such as Intrusion Detection and Prevention, Anti-virus, Anti-spam, Content/URL filtering and Application Detection.
"The combination of an Altera Stratix Series FPGA with high-performance regular expression processing is well suited to the continuously changing requirements of the content processing market," said Arun Iyengar, senior director of Altera’s communications business unit. "The RXP technology takes advantage of parallel processing, which enables it to scale to extremely high speeds, while offering scalability to be optimized for various market requirements."
Titan IC Systems and Altera will be demonstrating the RXP at the NXTcomm trade show in Las Vegas on 16 - 19th June 2008. Anyone interested in seeing a demonstration of the system and learning more about its capabilities is invited to come to the Titan IC Systems booth (SL1909).
About Titan IC Systems Ltd
Titan IC Systems is a leading technology innovator in the area of regular expression for content processing. It has developed a unique capability offering a flexible, yet high-performance solution for content processing for next-generation high-speed networks. Titan IC Systems has its headquarters in Belfast, Northern Ireland and a U.S. office in Sunnyvale, CA.
Altera, The Programmable Solutions Company, the stylized Altera logo, specific device designations and all other words that are identified as trademarks and/or service marks are, unless noted otherwise, the trademarks and service marks of Altera Corporation in the U.S. and other countries. All other product or service names are the property of their respective holder.
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
Information provided by: Findarticles.com
Former MessageLabs Executive Joins Webroot to Support Demand for Webroot[R] Security SaaS Solutions
BOULDER, Colo. — Webroot, a leading provider of security software for the consumer, enterprise and SMB markets, today announced the appointment of Brian Czarny as Vice President of Solutions Marketing. Czarny will play an integral role in advancing Webroot’s innovations in the rapidly growing security software as a service (SaaS) market by leading product management and product marketing.
"With malware threats growing 500 percent year over year and every business e-mail inbox expected to get hit with more than 42,000 spam messages, businesses are recognizing the need to take a more proactive approach to protecting their networks," said Mike Irwin, COO, Webroot. "It’s no surprise that we’re seeing a rapid increase in demand for security solutions that deliver more effective protection with lower cost of ownership and better manageability. Brian’s significant breadth and depth of experience in e-mail and Web security SaaS will be a great asset to the company as we continue to expand our portfolio to deliver solutions that meet and exceed these requirements."
Czarny brings to Webroot an extensive background in building and executing go-to-market strategies for e-mail and Web security SaaS solutions. He most recently led marketing for Code Green Networks, where as Vice President of Marketing he drove the adoption of the company’s data loss prevention solutions for small and medium-sized organizations seeking to protect personal information and safeguard confidential data.
Previously, Czarny was Vice President of Global Product Management at MessageLabs, where he drove the product strategy for the company’s email and Web security SaaS offerings sold to more than 16,000 organizations of all sizes and more than 7 million users around the world. In that role, Czarny was directly responsible for managing global product management and product marketing, expanding the company’s SaaS offerings within email while pioneering new markets for SaaS, such as Web security delivered as a service.
Prior to MessageLabs, Czarny held a number of senior marketing management positions at established and emerging technology companies including CS Technology and DirectWeb, a startup software and hardware as a service company.
Czarny has been regularly quoted as an industry expert on a range of security and messaging topics in media and broadcast outlets around the world including The New York Times, Wall Street Journal, Business Week, Information Week, eWeek, CNN, ABC 20/20, and CNBC. Czarny holds Bachelor of Arts degrees in Journalism and Political Science from Pennsylvania State University. He is based out of Webroot’s offices in Mountain View, California.
About Webroot
Webroot provides industry-leading security solutions to consumers, enterprises and small to medium-sized businesses worldwide. The Boulder, Colorado based company’s software-as-a-service (SaaS) offering, Webroot E-Mail Security SaaS, provides better manageability, better value and better protection than any other e-mail security solution available. Webroot’s award-winning endpoint products, Webroot AntiSpyware Corporate Edition and Webroot AntiSpyware Corporate Edition with AntiVirus are comprehensive, centrally-managed solutions that aggressively block, detect and eradicate malware on desktops across the network. To find out more visit www.webroot.com or call 800.772.9383.
(c)2008 Webroot Software, Inc. All rights reserved. Webroot is a registered trademark or trademark of Webroot Software, Inc. in the United States and/or other countries. All other trademarks are properties of their respective owners.
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
Information provided by: Findarticles.com
SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ — Monogram Biosciences, Inc. today announced that data related to the enhanced performance of the company’s HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain. Trofile was introduced commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer’s first in class CCR5 antagonist, in August 2007. Recent enhancements to Monogram’s Trofile(TM) HIV co-receptor tropism assay have made it substantially more sensitive at identifying minor subpopulations of CXCR4-using virus (X4 or dual/mixed (D/M) tropic) that may portend treatment failure with CCR5 antagonists. The Trofile assay is now capable of detecting CXCR4 tropic virus existing at levels as low as, or in some cases lower than, 0.3% of the total virus population. At levels of X4 using virus as low as 0.3%, Trofile is 100% sensitive.
"The CCR5 antagonist class of drugs has become an important addition to the choice of therapies for treatment of HIV," said Eric Daar, M.D., Chief of HIV Medicine at Harbor-UCLA Medical Center. "Selecting the right patients is critical, not just for the appropriate use of CCR5 antagonists but also to protect the other drugs in the patient’s regimen from unnecessary exposure to the development of resistance. The availability of Trofile with enhanced sensitivity now provides further confidence for physicians that treatment choices can be properly assessed."
In an oral presentation during the session on "New Resistance Technologies and Interpretations," Monogram scientist Dr. Jacqueline Reeves presented an analysis of subjects from the AIDS Clinical Trials Group 5211 (ACTG 5211) study. ACTG 5211 was a phase II study of Schering Plough’s CCR5 antagonist, vicriviroc, in highly treatment experienced HIV patients. This new analysis compared treatment outcomes based on the prospective selection of patients with R5 tropic virus by the original Trofile test versus treatment outcomes based on the re-classification using the enhanced version of the assay.
The ACTG 5211 study enrolled subjects who had R5 virus at screening as determined by the original Trofile assay. The analysis reported at this week’s workshop demonstrated that recent enhancements to Trofile enable the assay to further optimize patient selection for CCR5 antagonist treatment by successfully identifying patients that experienced reduced virologic response to vicriviroc. In the patients originally identified as R5 tropic, based on test results obtained with the newly enhanced sensitivity of Trofile, greater reductions in viral load were observed in vicriviroc recipients confirmed to have pure R5 virus populations (1.95 log reduction at week 24) compared to those newly re-classified as having minor subpopulations of CXCR4-using virus (0.57 log reduction at week 24) (P<0.001).
Additional work described at the meeting focused on the use of Monogram’s phenotypic and genotypic technology to identify specific markers of HIV resistance to new drug targets/classes. Monogram has assays in advanced development that accurately assess resistance to CCR5 antagonists such as maraviroc (Selzentry, Pfizer) and vicriviroc (Schering-Plough), and integrase inhibitors such as raltegravir (Isentress, Merck) and elvitegravir (Gilead Sciences).
Trofile, incorporating sensitivity enhancements, together with PhenoSense(TM), PhenoSenseGT(TM) and GeneSeq(TM) HIV drug resistance assays constitute Monogram’s portfolio of assays for the optimization of antiretroviral therapy for HIV infection. Determining a patient’s HIV profile at the molecular and phenotypic level, and the effect of therapy on that profile, is not only an invaluable part of patient selection for clinical trials, it is also critical to the pre-clinical evaluation of new drug candidates and for optimizing the selection of approved treatments for patient management in routine clinical practice.
About Trofile
Trofile is a clinically validated patient selection tropism assay that determines whether a patient is infected with a strain of HIV that uses either the CCR5 co-receptor (R5), the CXCR4 co-receptor (X4), or a combination of CCR5 and CXCR4 (D/M) to enter cells. The use of CCR5, CXCR4 or both co-receptors defines the "tropism" of the virus strain. Trofile amplifies the entire envelope gene from a patient’s HIV genome (from their blood sample) and then uses it to make HIV particles containing the patient’s virus envelope protein. The resultant HIV particles are then used to infect cells that contain the CCR5 co-receptor or the CXCR4 co-receptor on the cell surface. Once the virus infects the cell, it undergoes a single round of replication. Virus replication results in the production of luciferase from a luciferase gene that is carried into the cell by the virus. The production of luciferase in either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor tropism of the patient virus. Trofile is the only clinically validated tropism assay and has been used to select patients in all phase II and phase III studies of CCR5 antagonists to date.
Information provided by: Findarticles.com
SAN DIEGO, June 16 /PRNewswire-FirstCall/ — Vical Incorporated announced today the publication of results demonstrating that pandemic influenza DNA vaccines formulated with the company’s patented Vaxfectin(R) adjuvant provided complete protection of mice and ferrets against lethal challenge with a highly pathogenic strain of H5N1 influenza virus. The publication of the data in the June 15 issue of The Journal of Infectious Diseases (JID)(1) expands previously reported results supporting human clinical testing of the vaccine candidates.
"We believe DNA vaccines offer significant advantages over conventional approaches," said Vijay B. Samant, Vical’s President and Chief Executive Officer. "The publication of our pandemic influenza vaccine animal challenge data in a peer-reviewed scientific journal illustrates the approaches we are currently pursuing in our Phase 1 trial, and we look forward to releasing initial results from this study by August. This trial is also important because it marks the first time in humans for our Vaxfectin(R) adjuvant, which has potential applications with both DNA vaccines and conventional protein- based vaccines."
DNA vaccines can be adapted quickly to target emerging strains of influenza, manufactured in a few weeks in generic fermentation equipment, and stored for extended periods of time.
Highlights of the JID article include:
* A single injection of the company's three-component DNA vaccine
provided complete protection from death and disease in ferrets against
lethal challenge with the A/Vietnam/1203/04 strain of H5N1 influenza
virus.
* The three-component vaccine significantly decreased viral shedding in
ferrets. Reducing viral shedding, which is the primary cause of
disease transmission, could be critically important in limiting the
scope of a pandemic.
* A one-component H5 version of Vical's vaccine provided complete
protection from death in mice against lethal challenge with the H5N1
influenza virus. A prior Vical publication showed that one-component H3
or H1 vaccines also provided complete protection from death in mice
against lethal challenge with H3N2 or H1N1 strains of influenza virus.
Vical’s three-component pandemic influenza DNA vaccine candidate targets two "conserved" and one "variable" influenza virus proteins. Vical’s one- component DNA vaccine candidate targets only the variable influenza virus protein.
The company is currently conducting a double-blind, placebo-controlled Phase 1 trial of three-component and one-component Vaxfectin(R)-formulated DNA pandemic influenza vaccines to evaluate safety, tolerability and immune responses in approximately 100 healthy volunteers. Vical has completed enrollment in the Phase 1 trial and expects to release initial results by August.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com/.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the Vaxfectin(R)-formulated pandemic influenza DNA vaccine candidates; whether the vaccine candidates will be safe and tolerable, or effective in eliciting immune responses; whether H5N1 or other strains of influenza will emerge as pandemic threats; whether the Vaxfectin(R) adjuvant will be applied with other vaccine candidates; whether results from the pandemic influenza vaccine studies will be predictive of results in other vaccine applications; whether the company’s DNA vaccine candidates will be effective in protecting humans against H5N1 or other strains of influenza or in reducing viral shedding; whether results in mouse and ferret studies will be predictive of results in human studies; whether the influenza vaccine candidates or any other product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market the influenza vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing an influenza vaccine or any other product candidates; and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Information provided by: Findarticles.com
ROCKVILLE, Md., June 16 /PRNewswire-FirstCall/ — Novavax, Inc. a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Piper Jaffray Europe conference at 11:20 am. (GMT) on June 24, 2008 at The ANdAZ Hotel in London, UK. Dr. Singhvi will provide an overview of the company’s strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com/. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.
ABOUT NOVAVAX
Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing a new, efficient manufacturing solution. Additional information about Novavax is available at http://www.novavax.com/ and in the Company’s various filings with the Securities and Exchange Commission.
CONTACT: Tricia J. Richardson of Novavax, Inc., +1-240-268-2031
Web site: http://www.novavax.com/
COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning
Information provided by: Findarticles.com